Sionna Therapeutics (SION) Chief Business Officer gets options grant

Rhea-AI Filing Summary

Sionna Therapeutics Chief Business Officer Caroline Stark Beer was granted a non-qualified stock option for 139,340 shares of common stock. The option was awarded on January 2, 2026 with an exercise price of $39.21 per share. All 139,340 derivative securities are reported as directly owned following the transaction.

The shares underlying this option vest in forty-eight equal monthly installments after January 2, 2026, and each monthly vesting requires her continued service on that date. This filing reflects an equity compensation award rather than a sale of existing shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Beer Caroline Stark

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	139,340	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 139,340 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beer Caroline Stark

(Last) (First) (Middle)

C/O SIONNA THERAPEUTICS, INC.

21 HICKORY DRIVE, SUITE 500

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sionna Therapeutics, Inc. [ SION ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$39.21	01/02/2026		A		139,340		(1)	01/01/2036	Common Stock	139,340	$0.0	139,340	D

Explanation of Responses:

1. The shares underlying this option vest in forty-eight equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

	Jennifer Fitzpatrick, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sionna Therapeutics (SION) report in this Form 4?

The filing reports that Chief Business Officer Caroline Stark Beer received a grant of a non-qualified stock option to acquire 139,340 shares of Sionna Therapeutics common stock.

What is the exercise price of the stock options granted to Caroline Stark Beer at Sionna Therapeutics (SION)?

The non-qualified stock option granted to Caroline Stark Beer has an exercise price of $39.21 per share for Sionna Therapeutics common stock.

When was the stock option granted to the Sionna Therapeutics (SION) Chief Business Officer?

The non-qualified stock option for 139,340 shares was granted to Chief Business Officer Caroline Stark Beer on January 2, 2026.

How do the Sionna Therapeutics (SION) stock options granted to Caroline Stark Beer vest?

The shares underlying the option vest in forty-eight equal monthly installments following January 2, 2026, and each vesting is conditioned on Caroline Stark Beer’s continued service on the applicable vesting date.

How many derivative securities does Caroline Stark Beer hold in Sionna Therapeutics (SION) after this transaction?

After the grant, Caroline Stark Beer beneficially owns 139,340 derivative securities (non-qualified stock options) directly.

Is the Sionna Therapeutics (SION) Form 4 transaction a purchase or a grant of options?

The Form 4 reflects an award of non-qualified stock options coded as an acquisition (code A), not an open-market purchase or sale of existing shares.